Objectives. The aim of this study was to describe heart transplantation in children with congenital heart disease and to compare the results with those in children undergoing transplantation for other cardiac diseases.
Surgical advances have greatly increased the survival of children with congenital heart disease. However, myocardial failure can occur early or late after operation for complex congenital heart disease. Late cardiac mortality has been reported after surgical repair of tetralogy of Fallot (5%), aortic stenosis (17%) and the Mustard procedure for transposition of the great arteries (15%) (1). Fontan et al. (2) reported an increase in risk of death from 6 to 15 years after the Fontan operation.
As survival after heart transplantation has improved, this option is more often considered in the surgical management of children with complex congenital heart disease. According to the registry of the International Society for Heart Transplantation (3), congenital heart disease has become the primary indication for transplantation in the pediatric population, with the proportion of children with congenital heart disease undergoing transplantation increasing from 16% in 1984 to 46% in 1993. Beyond the neonatal age range, most children with congenital heart disease undergoing transplantation have undergone one or more attempts at palliative or corrective cardiac surgery. Heart transplantation in these children presents a number of special problems. The indications and optimal timing of transplantation can be ditficult to determine in patients with complex heart disease, and the type of reconstructive surgery of extracardiac defects required at transplantation must be carefully considered. Previous studies have reported many unique technical approaches to heart transplantation in patients with systemic and pulmonary venous anomalies (4) (5) (6) , pulmonary artery stenoses (7), hypoplastic left heart syndrome (8) , dextrocardia (9) and transposition of the great arteries (10) (11) (12) .
It has been reported (13, 14) that mortality among children with congenital heart disease is higher than that for children undergoing transplantation for other reasons, but recent studies (15, 16) have shown improved survival. The present study describes the pretransplantation and posttransplantation courses of a relatively large series of children with and without congenital heart disease undergoing transplantation and compares their outcome.
Methods
Patients. Eighty-four consecutive children undergoing primary heart transplantation from June 1984 to August 1993 were included in the present study (44 boys, 40 girls; mean [_+SD] age at time of transplantation 9.3 _+ 6.2 years, range 1 week to 18.5 years; mean follow-up time from transplantation 37 _+ 31 months, range of 0.1 to 122). The follow-up period ended in July 1994. Two patients underwent heterotopic heart transplantation because of severely elevated pulmonary vascular resistance, and 82 underwent orthotopic transplantation.
Indication for heart transplantation. Congenital heart disease with intractable congestive heart failure or complex congenital heart disease with severe deterioration not amenable to surgical correction were the indications for transplantation in 37 patients (44%). Thirty-four patients were older than 6 months of age at the time of operation. The number of children per year with the diagnosis of congenital heart disease undergoing transplantation at our institution increased from 2 patients in 1984 to 10 in 1992. For the 47 patients without congenital heart disease, the indication for transplantation was congestive heart failure refractory to maximal medical therapy. The underlying diagnoses of these patients were dilated cardiomyopathy (27 patients), endocardiofibroelastosis (7 patients), hypertrophic cardiomyopathy (7 patients) and adriamycin-induced cardiomyopathy (5 patients). One additional patient underwent transplantation because of congestive heart failure and ventricular arrhythmias secondary to an unresectable left ventricular tumor.
Study groups. The patients were classified into two groups for comparison; those with congenital heart disease and those with other cardiac diseases. The following preoperative variables were compared between the two groups: gender, age at transplantation, duration of congestive heart failure before transplantation, number of inotropic medications required and pulmonary vascular resistance index before transplantation. The posttransplantation variables of donor heart ischemia time, cardiopulmonary bypass time, patient survival, duration of posttransplantation hospital stay, rejections per patientmonth and serious bacterial or fungal infections requiring 3% 5%
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intravenous antibiotic agents in the early postoperative (<3 months) period were also compared between the two groups. The incidence of graft atherosclerosis and lymphoproliferative disorders was also compared. Immunosuppression protocol. Before 1986, all children undergoing transplantation (n = 14) were maintained on cyclosporine (serum trough levels of 150 to 200 ng/dl) and prednisone (0.2 mg/kg body weight per day). Six of these children had congenital heart disease, and eight had cardiornyopathy. After November 1986, azathioprine was added to the protocol in doses of 1.5 to 2 mg/kg per day, and cyclosporine trough levels were maintained at 200 ng/dl (n = 70). Endomyocardial biopsies were performed on a routine basis, and histologic evidence of acute rejection was treated with increased corticosteroid doses. Refractory episodes of rejection were treated with OKT3, rabbit ATG, methotrexate or total lymphoid irradiation, as clinically indicated.
Statistical analysis. Continuous variables were compared between patients with and without congenital heart disease by unpaired t test. Chi-square analysis was used to compare discrete variables. Survival between the two groups was compared using the Wilcoxon and log-rank tests for the association of response with covariates. The power of the study to detect a 10% difference in survival was 30%.
Results
Patients with congenital heart disease. Diagnoses, surgical histories and indications for transplantation. The mean (_+SD) age of the 37 children with congenital heart disease who underwent transplantation was 9.3 _+ 6.4 years with a mean length of follow-up of 31.2 _+ 29 months. The diagnoses and surgical histories of these children are presented in Table 1 .
Five patients had not undergone cardiac surgery before transplantation. Reparative surgery was not feasible in two newborns; three patients developed severe ventricular dysfunction in addition to their congenital heart defect ( Table 2) . Thirty-two patients (86%) developed significant ventricular failure after palliative or corrective surgery. Eight patients were in New York Heart Association functional class III at the time of transplantation; 29 were in class IV. Twenty-six (70%) of the 37 patients were receiving a mean of 1.8 (range 1 to 5) inotropic agents at the time of transplantation; eight were mechanically ventilated. Twenty-two patients (60%) had undergone two or more cardiac procedures, and five previous operations had been performed in each of two patients (Fig. 1) . Closed heart procedures were performed before transplantation in 20 patients (54%); the most common procedure was an aortopulmonary shunt (Fig. 2) . Heart transplantation was performed after a closed heart procedure alone in seven patients, in six after an aortopulmonary shunt and in one after pulmonary artery banding. The remaining 13 patients underwent one or more additional cardiac surgical procedures before transplantation.
Twenty-five patients (68%) had undergone a mean of 1.6 _+ 0.7 open heart surgeries before heart transplantation. The mean interval from the last open heart procedure to transplantation was 3.4 +_ 3.0 years. Thirteen patients had undergone one or more operations to correct their congenital heart defect; 12 patients with a single ventricle had undergone palliative open heart surgery (Fig. 3) .
Additional surgical procedures performed at the time of transplantation included takedown of a Fontan or Glenn procedure, repair of pulmonary artery stenosis and rerouting of the systemic or pulmonary venous return (Table 3) . In all patients who required reconstruction of the systemic venous return, endomyocardial biopsies could be performed, when necessary, through the rerouted superior or inferior vena cava.
Mortality and cause of death. Thirteen of the 37 patients with congenital heart disease died after transplantation, 11 (85%) within 9 months after the procedure. Causes of death included donor heart failure, right heart failure secondary to pulmonary hypertension, postoperative hemorrhage, pulmonary hemorrhage, infection, rejection and graft atherosclerosis (Table 4) . Of the three late deaths, one resulted from pneumonia after a prolonged hospital stay, and two occurred in adolescents who died at 40 and 92 months posttransplantation because of noncompliance with their immunosuppression protocol.
Residual extracardiac defects. Four patients had the presence of aortopulmonary collateral channels documented by descending aorta angiography after transplantation. Three had undergone a Fontan procedure, and one had two previous Blalock-Taussig shunts placed for severe pulmonary stenosis in the context of a polysplenia syndrome. In three of the four patients, high output heart failure developed within 2 weeks of transplantation, necessitating increased inotropic support and coil embolization of the major collateral channels.
Functional status. Twenty-two of the 25 patients currently alive are participating fully in age-appropriate activities. One 11-year old patient is limited by severe scoliosis and restrictive lung disease and attends school half-time. Two preschool children are mildly hypotonic and are undergoing physical therapy for delayed gross motor function.
Comparison: Patients with and without congenital heart disease. Preoperative variables. The pretransplantation clinical profiles of the patients with and without congenital heart disease indicated no significant difference between the groups with respect to age at transplant, gender, duration of congestive heart failure or number of inotropic medications required before transplantation (Table 5 ). The mean pulmonary vascular resistance index was relatively high for both groups, but there was no significant difference between the two groups.
Patient survival. There was no significant difference in patient survival between the two groups (Fig. 4) . Three patients with congenital heart disease have undergone retransplantation for ventricular failure secondary to chronic rejection; however, overall graft survival was also not significantly different between the two groups. Regardless of diagnosis, overall survival after transplantation was significantly lower in all patients undergoing transplantation before mid-1986 compared with those undergoing transplantation since mid-1986. Only 2 (14%) of 14 children who underwent transplantation before mid-1986 still survive compared with 53 (75%) of 70 children who underwent transplantation since mid-1986. However, survival was not significantly different between patients with congenital heart disease and those with other cardiac diseases undergoing transplantation before mid-1986 (none of six vs. two of eight survivors). Similarly, no difference in survival was seen by diagnosis among patients undergoing transplantation after mid-1986. Ten of the 12 deaths that occurred in the patients who underwent transplantation before mid-1986 were due to rejection, whereas 3 of 17 deaths after mid-1986 were secondary to rejection. Thus, the type of immunosuppression was significantly associated with the difference in survival between the two time periods (17) .
lntraoperative and postoperative variables. Intraoperative and postoperative variables were compared between the patients with and without congenital heart disease ( Table 6 ). Graft ischemia time and cardiopulmonary bypass time were significantly longer in patients with congenital heart disease. The number of patients with an early bacterial or fungal infection after transplantation was significantly higher in the group with than without congenital heart disease (13 of 37 vs. 6 of 47, respectively). The infections seen in the group with congenital heart disease included bacterial sepsis (eight patients), bacterial and Candida albicans sepsis (two patients), Staphylococcus aureus and Aspergillus empyema (one patient), toxoplasmosis (one patient) and bacterial pneumonia (one patient).
Coronary artery disease and lymphoproliferative disease. The incidence of graft atherosclerosis was no different between Data presented are mean value + SD or number of patients. CHD : congenital heart disease; CHF = congestive heart failure; pt = patient; PVRI = pulmonary vascular resistance index. children with and without congenital heart disease. Sixty of the 84 patients had selective coronary artery angiography or postmortem histologic examination of the coronary arteries of the transplanted heart. Five of 23 patients with and 5 of 37 patients without congenital heart disease had evidence of graft atherosclerosis.
Lymphoproliferative disorders have been diagnosed in 5 of the 84 patients in the present study. Three patients had the pretransplantation diagnosis of congenital heart disease, and two patients underwent transplantation because of end-stage congestive heart failure secondary to cardiomyopathy.
Discussion
Transplantation for congenital heart disease. The present study describes the use of transplantation as a surgical approach to children with congenital heart disease and end-stage heart failure. The majority of patients were outside the neonatal period and had undergone previous palliative or corrective surgery. Most patients had the clinical findings of severe ventricular dysfunction and were critically ill in the intensive care unit at the time of transplantation. Thus, expected 1-year survival in this patient group without transplantation was extremely low, in contrast to the 1-year survival of 70% and 5-year survival of 64% after transplantation.
Early studies suggested that congenital heart disease was an independent risk factor for death after heart transplantation in children outside the neonatal age range. Trento et al. (14) reported 4 survivors after transplantation in 10 patients with congenital heart disease; four of the six deaths were attributed to donor right heart failure. Right ventricular decompensation has also been reported as a cause of death in other series (18) (19) (20) . Although the mean pulmonary vascular resistance index of the patients in the present study was 6.0 units, only one patient died of donor right heart failure. As previously reported from this institution (2l), aggressive pretransplantation and posttransplantation measures to lower pulmonary vascular resistance and prevent donor right heart failure most likely contributed to the lower incidence of death from right heart failure. In a follow-up study by Armitage Figure 4 . Patient survival after transplantation in patients with and without congenital heart disease (CHD).
additional patients with congenital heart disease were added to the original 10 patients, and the improved 1-year survival of 60% was attributed to "improved myocardial protection, surgical experience and more aggressive post-transplant care" (15) . Reported 1-year survival after transplantation in children with congenital heart disease ranges from 3 of 11 patients reported by Baum et al. (19) to 9 of 10 patients reported by Chartrand (18) . The 70% 1-year survival rate in the present series is similar to that of 53% to 71% reported by other investigators (9, 13, 16) . The majority (83%) of deaths in the present series occurred early after transplantation, although only two deaths from postoperative hemorrhage could be directly attributed to the complexity of the structural heart disease. The 5-year survival of 64% in the present study is also comparable to long-term survival after transplantation reported in the other smaller series (13, 15, 16) .
Additional reconstructive surgery was performed at the time of transplantation in 62% of the patients in the present series. Many innovative techniques have been described (4) (5) (6) (7) (8) (9) (10) (11) (12) to reconstruct and repair extracardiac defects. However, to our knowledge comparison of donor ischemia time and cardiopul- monary bypass time between patients with and without congenital heart disease has not been reported previously. In the present study, both donor heart ischemia time and cardiopulmonary bypass time were longer in the patients with congenital heart disease, implying that the time required for reconstructive surgery before transplantation contributed to the duration of graft ischemia. Improved coordination of the timing of organ donor procurement to increase the operative time allotted to prepare the recipient with congenital heart disease for transplantation may help shorten donor ischemia time.
Infections. The incidence of significant postoperative infections in our patients with congenital heart disease was 35%. The most common infection was bacterial sepsis, although three patients did have fungal sepsis. Ten of the 13 patients had undergone previous cardiac surgery, which may have led to slower wound healing because of decreased vascularity of scar tissue and a predisposition to infection; however, the etiology of the increased susceptibility to infection in these patients is not clear. Aortopulmonary collateral channels. The incidence of aortopulmonary collateral channels in patients is reported (22) to be 36% in patients after the Fontan or bidirectional Glenn procedure. Aortopulmonary collateral channels have not been reported after transplantation for congenital heart disease. The incidence in the present series was similarly 33% (3 of 9) in the patients after a Fontan procedure; two patients developed significant hemodynamic compromise and required catheter embolization of the collateral channels.
Summary. Transplantation should be considered under various circumstances for the child with complex congenital heart disease. The decision to replace rather than to attempt palliation or repair in very high risk cases must be tailored to the individual patient, weighing the complexity of the reparative surgery and the possibility of success against the risks of the transplant operation and consequences of long-term immunosuppression in the pediatric patient. Some children have no other options because all other operative choices have been exhausted. At our institution, the only anatomic contraindication to heart transplantation is severe pulmonary artery hypoplasia or pulmonary vein stenosis. The present study demonstrates that despite longer graft ischemia and bypass times and a higher incidence of postoperative infections, survival after transplantation in children with congenital heart disease is comparable to survival after transplantation in children with other cardiac diseases, predominantly cardiomyopathy. Transplantation was performed successfully in six of nine patients with a "failed" Fontan procedure, offering these severely debilitated patients the possibility of a return to normal activities. In addition, six of nine patients with single-ventricle anatomy in whom a Fontan procedure was contraindicated also survived transplantation. Our data demonstrate that heart transplantation offers the possibility of excellent medium-term survival for children with a variety of complex congenital heart lesions and should be considered as a therapeutic option in children with myocar-dial dysfunction or in those patients with no other viable options.
